George Perdikis, MD
Pain Management · Ridgecrest, CANPI 1336178128
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 180 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by Forte Bio-pharma LLC at 34.9% of the total. Among pain management clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 180 payments — averaging $17.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Forte Bio-pharma LLC$1K
- Virtus Pharmaceuticals LLC$392
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$324
- Amgen$231
- AbbVie$182
- Daiichi Sankyo Inc.$173
- plus $778 from 12 others
What the payments were for
- Food & beverage$3,197100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Forte Bio-pharma LLC | 75 | $1,117 |
| Virtus Pharmaceuticals LLC | 16 | $392 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 17 | $324 |
| Amgen | 7 | $231 |
| AbbVie | 7 | $182 |
| Daiichi Sankyo Inc. | 10 | $173 |
| Supernus Pharmaceuticals, Inc. | 14 | $154 |
| Biohaven Pharmaceuticals, Inc. | 8 | $151 |
| Eisai Inc. | 6 | $110 |
| Idorsia Pharmaceuticals US Inc | 5 | $97 |
| Pfizer | 5 | $87 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $51 |
| Redhill Biopharma Inc. | 2 | $32 |
| Sanofi | 1 | $30 |
| Indivior Inc. | 1 | $24 |
| Vertex | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Amneal Pharmaceuticals LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIMOVIG$125
How this compares
$3,197 in reported general payments places this provider in the 95th percentile of 26 pain management providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levorphanol Tartrate | 25 | $85,929 |
| MysolinePrimidone | 14 | $78,226 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 374 | $27,925 |
| OxycontinOxycodone Hcl | 35 | $15,199 |
| Hydromorphone Hcl | 317 | $15,052 |
| Fentanyl | 114 | $14,641 |
| Diclofenac Sodium | 76 | $12,925 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 606 | $11,026 |
| MovantikNaloxegol Oxalate | 20 | $9,770 |
| Morphine Sulfate ErMorphine Sulfate | 211 | $7,904 |
| Oxycodone Hcl | 210 | $6,884 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 12 | $5,933 |
| Gabapentin | 444 | $3,865 |
| Lidocaine | 66 | $3,496 |
| Baclofen | 268 | $2,536 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Virtus Pharmaceuticals LLCLevorphanol Tartrate | $392 | $85,92925 claims |
| Redhill Biopharma Inc.Movantik | $32 | $9,77020 claims |
| Indivior Inc.Suboxone | $24 | $5,93312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 26 pain management providers in California.
Other pain management in Ridgecrest
- Timothy MansouriFolsom$3K
- Doanh NguyenWestminster$2K
- Alexander Krakovskyla Jolla$935
- Anthony TranLos Angeles$454
- Kellie BinderOrange$315
- Nimish ShahHawaiian Gardens$292
- Jennifer ZubickPalmdale$291
- Carolyn HiranoLos Gatos$121
- Peter SchmidtStanford$0
- Sean MackeyStanford$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.